Kim Payne to Precursor Cell Lymphoblastic Leukemia-Lymphoma
This is a "connection" page, showing publications Kim Payne has written about Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Connection Strength
1.336
-
Ikaros and tumor suppression in acute lymphoblastic leukemia. Crit Rev Oncog. 2011; 16(1-2):3-12.
Score: 0.341
-
Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemia. Leukemia. 2021 05; 35(5):1267-1278.
Score: 0.172
-
IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia. Blood. 2020 09 24; 136(13):1520-1534.
Score: 0.168
-
The Current Genomic and Molecular Landscape of Philadelphia-like Acute Lymphoblastic Leukemia. Int J Mol Sci. 2020 Mar 22; 21(6).
Score: 0.162
-
Ikaros tumor suppressor function includes induction of active enhancers and super-enhancers along with pioneering activity. Leukemia. 2019 11; 33(11):2720-2731.
Score: 0.152
-
High CRLF2 expression associates with IKZF1 dysfunction in adult acute lymphoblastic leukemia without CRLF2 rearrangement. Oncotarget. 2016 Aug 02; 7(31):49722-49732.
Score: 0.126
-
Co-existence of IL7R high and SH2B3 low expression distinguishes a novel high-risk acute lymphoblastic leukemia with Ikaros dysfunction. Oncotarget. 2016 Jul 19; 7(29):46014-46027.
Score: 0.125
-
Cell cycle-specific function of Ikaros in human leukemia. Pediatr Blood Cancer. 2012 Jul 15; 59(1):69-76.
Score: 0.091